Chiasma, a biotech developing oral therapies for orphan diseases only treated by injections, raised $102 million by offering 6.4 million shares (100% primary) at $16, above the $13-$15 range. Chiasma sold 1.0 million more shares than originally planned.
At its offer price, Chiasma commands a fully diluted market cap of $450 million. It will list on the NASDAQ under the symbol CHMA. Barclays and Cowen & Company acted as lead managers on the deal.
The article Chiasma prices upsized IPO at $16, above the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.